molybdenum cofactor deficiency type A

临床试验

计划入组 10 人 · 首次发布于 2009 年 8 月 12 日

已完成

NCT02629393

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

计划入组 5 人 · 首次发布于 2015 年 12 月 14 日

已完成

NCT02047461

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

计划入组 8 人 · 首次发布于 2014 年 1 月 28 日

药物

查看全部 6422 →

Small Molecule

Approved

Fosdenopterin(Nulibry)

相关疾病：Molybdenum Cofactor Deficiency, Type A

C₁₀H₁₄N₅O₈P

Small Molecule

Experimental

Molybdenum cofactor

C₁₀H₁₀MoN₅O₈PS₂

Small Molecule

Approved

Molybdenum

Mo

机构

查看全部 4009 →

A&A SMALL CHANGES HANDYPEOPLE

United States

Novozymes A/S

Denmark

Ambu A/S

Denmark

资讯

查看全部 40735 →

去年

NULIBRY Shows Significant Survival Benefits in Ultra-Rare MoCD Type A: Landmark Clinical Evidence Published

2年前

BridgeBio Refocuses on Late-Stage Assets, Trims Pipeline to Sharpen Commercial Focus

去年

临床试验

Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

药物

Fosdenopterin(Nulibry)

Molybdenum cofactor

Molybdenum

机构

A&A SMALL CHANGES HANDYPEOPLE

Novozymes A/S

Ambu A/S

资讯

NULIBRY Shows Significant Survival Benefits in Ultra-Rare MoCD Type A: Landmark Clinical Evidence Published

BridgeBio Refocuses on Late-Stage Assets, Trims Pipeline to Sharpen Commercial Focus

OncoPrism-HNSCC RNA Test Shows Improved Prediction of Immunotherapy Response in Head and Neck Cancer